Thyroid Disease

First Treatment for Thyroid Eye Disease Gets FDA Approval

The Food and Drug Administration (FDA) has approved Tepezza™ (teprotumumab-trbw; Horizon Therapeutics) for the treatment of thyroid eye disease. Tepezza™, a fully human monoclonal antibody, works by binding to insulin-like growth factor 1 receptor and blocking its activation and signaling. The treatment is administered as an intravenous infusion. The approval of Tepezza™ was supported by…

FDA: Thyroid Medications Recalled Due to Inconsistent Potency

Westminster Pharmaceuticals announced a recall of all lots of Levothyroxine and Liothyronine (Thyroid Tablets) 15mg, 30mg, 60mg, 90mg, 120mg as the product was manufactured using active pharmaceutical ingredients (API) from a company that was found to have deviated from the Food and Drug Administration (FDA)’s Good Manufacturing Practices. FDA laboratory tests confirmed Sichuan Friendly Pharmaceutical’s…